TABUTEAU HERRIOT 4
4 · Axsome Therapeutics, Inc. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
TABUTEAU HERRIOT
DirectorChief Executive Officer10% Owner
Transactions
- Exercise/Conversion
Common Stock
2026-01-05$8.02/sh+78,703$631,198→ 85,932 total - Sale
Common Stock
2026-01-05$171.28/sh−78,703$13,480,250→ 7,229 total - Exercise/Conversion
Common Stock
2026-01-06$8.02/sh+29,450$236,189→ 36,679 total - Sale
Common Stock
2026-01-06$172.33/sh−29,450$5,075,119→ 7,229 total - Exercise/Conversion
Common Stock
2026-01-07$8.02/sh+31,261$250,713→ 38,490 total - Sale
Common Stock
2026-01-07$170.38/sh−31,261$5,326,249→ 7,229 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-05−78,703→ 93,121 totalExercise: $171.28From: 2017-05-27Exp: 2026-05-27→ Common Stock (78,703 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-06−29,450→ 63,671 totalExercise: $172.33From: 2017-05-27Exp: 2026-05-27→ Common Stock (29,450 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-07−31,261→ 32,410 totalExercise: $170.38From: 2017-05-27Exp: 2026-05-27→ Common Stock (31,261 underlying)
Holdings
- 7,344,500(indirect: See Footnote)
Common Stock
Footnotes (7)
- [F1]Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $168.58 and $178.60.
- [F5]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $170.36 and $175.26.
- [F6]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $168.15 and $173.17.
- [F7]Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.